|
1
|
Dykstra DD, Sidi AA, Scott AB, Pagel JM
and Goldish GD: Effects of botulinum A toxin on detrusor-sphincter
dyssynergia in spinal cord injury patients. J Urol. 139:919–922.
1988.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Montecucco C and Molgó J: Botulinal
neurotoxins: Revival of an old killer. Curr Opin Pharmacol.
5:274–279. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Scott AB: Botulinum toxin injection of eye
muscles to correct strabismus. Trans Am Ophthalmol Soc. 79:734–770.
1981.PubMed/NCBI
|
|
4
|
Abrams P, Cardozo L, Fall M, Griffiths D,
Rosier P, Ulmsten U, van Kerrebroeck P, Victor A and Wein A:
Standardisation Sub-committee of the International Continence
Society. The standardisation of terminology of lower urinary tract
function: Report from the Standardisation Sub-committee of the
International Continence Society. Neurourol Urodyn. 21:167–178.
2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Irwin DE, Milsom I, Hunskaar S, Reilly K,
Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, et
al: Population-based survey of urinary incontinence, overactive
bladder, and other lower urinary tract symptoms in five countries:
Results of the EPIC study. Eur Urol. 50:1306–1315. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sacco E, Tienforti D, D'Addessi A, Pinto
F, Racioppi M, Totaro A, D'Agostino D, Marangi F and Bassi P:
Social, economic, and health utility considerations in the
treatment of overactive bladder. Open Access J Urol. 2:11–24.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Harper M, Fowler CJ and Dasgupta P:
Botulinum toxin and its applications in the lower urinary tract.
BJU Int. 93:702–706. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ha US, Park EY and Kim JC: Effect of
botulinum toxin on expression of nerve growth factor and transient
receptor potential vanilloid 1 in urothelium and detrusor muscle of
rats with bladder outlet obstruction-induced detrusor overactivity.
Urology. 78:721.e1–721.e6. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Frenkl TL and Rackley RR: Injectable
neuromodulatory agents: Botulinum toxin therapy. Urol Clin North
Am. 32:89–99. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ikeda Y, Zabbarova IV, Birder LA, de Groat
WC, McCarthy CJ, Hanna-Mitchell AT and Kanai AJ: Botulinum
neurotoxin serotype A suppresses neurotransmitter release from
afferent as well as efferent nerves in the urinary bladder. Eur
Urol. 62:1157–1164. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sampaio C, Ferreira JJ, Simões F, Rosas
MJ, Magalhães M, Correia AP, Bastos-Lima A, Martins R and
Castro-Caldas A: DYSBOT: A single-blind, randomized parallel study
to determine whether any differences can be detected in the
efficacy and tolerability of two formulations of botulinum toxin
type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord.
12:1013–1018. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Odergren T, Hjaltason H, Kaakkola S,
Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S,
Westergren I, et al: A double blind, randomised, parallel group
study to investigate the dose equivalence of Dysport and Botox in
the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry.
64:6–12. 1998.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ranoux D, Gury C, Fondarai J, Mas JL and
Zuber M: Respective potencies of Botox and Dysport: A double blind,
randomised, crossover study in cervical dystonia. J Neurol
Neurosurg Psychiatry. 72:459–462. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Drake MJ, Nitti VW, Ginsberg DA, Brucker
BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D and
Chapple CR: Comparative assessment of the efficacy of onabotulinum
toxin A and oral therapies (anticholinergics and mirabegron) for
overactive bladder: A systematic review and network meta-analysis.
BJU Int. 120:611–622. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ferreira RS, D'Ancona CA, Oelke M and
Carneiro MR: Intradetrusor onabotulinum toxin A injections are
significantly more efficacious than oral oxybutynin for treatment
of neurogenic detrusor overactivity: Results of a randomized,
controlled, 24-week trial. Einstein (Sao Paulo).
16(eAO4207)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schurch B, Denys P, Kozma CM, Reese PR,
Slaton T and Barron RL: Botulinum toxin A improves the quality of
life of patients with neurogenic urinary incontinence. Eur Urol.
52:850–858. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Karsenty G, Denys P, Amarenco G, De Seze
M, Gamé X, Haab F, Kerdraon J, Perrouin-Verbe B, Ruffion A,
Saussine C, et al: Botulinum toxin A (Botox) intradetrusor
injections in adults with neurogenic detrusor
overactivity/neurogenic overactive bladder: A systematic literature
review. Eur Urol. 53:275–287. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou X, Yan HL, Cui YS, Zong HT and Zhang
Y: Efficacy and safety of onabotulinum toxin A in treating
neurogenic detrusor overactivity: A systematic review and
meta-analysis. Chin Med J (Engl). 128:963–968. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bumbu A, Pasca B, Tit DM, Bungau S and
Bumbu G: The effects of soy isoflavones and hormonal replacing
therapy on the incidence and evolution of postmenopausal female
urinary incontinence. Farmacia. 64:419–422. 2016.
|
|
20
|
Koschorke M, Leitner L, Sadri H, Knüpfer
SC, Mehnert U and Kessler TM: Intradetrusor onabotulinum toxin A
injections for refractory neurogenic detrusor overactivity
incontinence: Do we need urodynamic investigation for outcome
assessment? BJU Int. 120:848–854. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang R, Xu Y, Yang S, Liang H, Zhang Y
and Liu Y: Onabotulinum toxin A for neurogenic detrusor
overactivity and dose differences: A systematic review. Int Braz J
Urol. 41:207–219. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Duthie JB, Vincent M, Herbison GP, Wilson
DI and Wilson D: Botulinum toxin injections for adults with
overactive bladder syndrome. Cochrane Database Syst Rev: Dec 7,
2011 (Epub ahead of print). doi:
10.1002/14651858.CD005493.pub3.
|
|
23
|
Denys P, Dmochowski R, Aliotta P,
Castro-Diaz D, Blok B, Ethans K, Aboushwareb T, Magyar A and
Kennelly M: Positive outcomes with first onabotulinum toxin A
treatment persist in the long term with repeat treatments in
patients with neurogenic detrusor overactivity. BJU Int.
119:926–932. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schurch B, de Sèze M, Denys P,
Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B,
Kumar C, Fraczek S, et al: Botox Detrusor Hyperreflexia Study Team:
Botulinum toxin type A is a safe and effective treatment for
neurogenic urinary incontinence: Results of a single treatment,
randomized, placebo controlled 6-month study. J Urol. 174:196–200.
2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hui C, Keji X, Chonghe J, Ping T, Rubiao
O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, et al:
Combined detrusor-trigone BTX-A injections for urinary incontinence
secondary to neurogenic detrusor overactivity. Spinal Cord.
54:46–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Abdel-Meguid TA: Botulinum toxin-A
injections into neurogenic overactive bladder - to include or
exclude the trigone? A prospective, randomized, controlled trial. J
Urol. 184:2423–2428. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cheng T, Shuang WB, Jia DD, Zhang M, Tong
XN, Yang WD, Jia XM and Li S: Efficacy and safety of onabotulinum
toxin A in patients with neurogenic detrusor overactivity: A
systematic review and meta-analysis of randomized controlled
trials. PLoS One. 11(e0159307)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Trinh H, Irish V, Diaz M and Atiemo H:
Outcomes of intradetrusor onabotulinum toxin A therapy in
overactive bladder refractory to sacral neuromodulation. Int
Neurourol J. 23:226–233. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Spinu D, Bratu O, Marcu D, Mischianu D,
Huica R, Surcel M, Munteanu A, Socea B, Bodean O and Ursaciuc C:
The use of ELISA and PCR in identifying correlations between viral
infections and benign prostatic hypertrophy. Rev Chim Buchar.
69:645–649. 2018.
|
|
30
|
Spinu D, Rădulescu A, Bratu O, Checheriţă
IA, Ranetti AE and Mischianu D: Giant condyloma acuminatum -
Buschke-Lowenstein disease - a literature review. Chirurgia
(Bucur). 109:445–450. 2014.PubMed/NCBI
|
|
31
|
Jhang JF and Kuo HC: Novel applications of
onabotulinum toxin A in lower urinary tract dysfunction. Toxins
(Basel). 10(260)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Manea M, Marcu D, Pantea Stoian A, Gaman
MA, Gaman AM, Socea B, Neagu TP, Stanescu AMA, Bratu OG and Diaconu
CC: Heart failure with preserved ejection fraction and atrial
fibrillation: A review. Rev Chim Buchar. 69:4180–4184. 2018.
|
|
33
|
Draghici T, Negreanu L, Bratu OG, Tincu R,
Socea B, Iancu MA, Stanescu AM and Diaconu C: Liver abnormalities
in patients with heart failure. Arch Balk Med Union. 53:76–81.
2018.
|
|
34
|
Liao CH, Wang CC and Jiang YH:
Intravesical onabotulinum toxin A injection for overactive bladder
patients with frailty, medical comorbidities or prior lower urinary
tract surgery. Toxins (Basel). 8(91)2016.PubMed/NCBI View Article : Google Scholar
|
